BioNano Genomics Appoints Terry Salyer As Chief Commercial Officer

SAN DIEGO, March 26, 2015 /PRNewswire/ -- BioNano Genomics, Inc., the leader in genome mapping, announced today the appointment of Terry Salyeras chief commercial officer. Salyer has more than 20 years of experience building highly effective, worldwide sales teams in life sciences. At BioNano, Salyer will oversee the commercialization of BioNano's Irys® System, a genome-mapping platform to assemble a comprehensive view of complex genomes to help discover and investigate structural variations. To date, 32 institutions located in the United States, Europe and Asia Pacific, already own an Irys System, and BioNano recently expanded its existing Asia-Pacific distribution to Japan.

"The ability to robustly discover structural variations and to complete genome assemblies has made BioNano's Irys System an essential tool to advance genomic research and applications," said Erik Holmlin, Ph.D., president and CEO of BioNano Genomics. "We look forward to working with Terry, who will lead and build BioNano's worldwide sales teams for significant growth and adoption of the Irys System."

Genome maps built using the Irys System can help reveal significant order and orientation of relevant genetic components that have biological and clinical relevance. These include genes, promoters, regulatory elements, the length and location of long areas of repeats, as well as viral integration sites. As a whole, these structural variations have been termed the "inaccessible genome," because they are often missed by the existing repertoire of genomics tools.

"I was impressed with how the Irys System allows scientists to reach the 'inaccessible genome' with a single, cost-effective technology platform," said Salyer. "The BioNano team has created the only commercial genome mapping system, and I look forward to helping genomics researchers access the Irys System to obtain a comprehensive view of complex genomes."

Prior to joining BioNano Genomics, Salyer was the vice president of worldwide sales at ProteinSimple where she doubled the revenue growth. Previous to ProteinSimple, she was vice president of worldwide sales at ForteBio, where she held a critical role in successfully selling the business to Pall Corporation. Salyer's previous positions include vice president of worldwide sales and service at Eksigent Technologies and director of sales at Molecular Devices. At Molecular Devices, Terry was director of the Western region and had responsibility for sales of all life sciences products. Terry holds a B.S. in biotechnology from Minnesota State at Mankato.

About Irys

Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long "reads" ranging from hundreds of kilobases to a megabase, where the sample's valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.

About BioNano Genomics

Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company's platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.

Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.

Photo -

To view the original version on PR Newswire, visit:

SOURCE BioNano Genomics